C. Oo

发表

There is no better time than the present: nanotechnology as a disruptive innovation for drug development.

J. Tsai, C. Oo, H. Kao, 2015, Drug discovery today.

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

C. Oo, Lorraine M. Rusch, 2016, Journal of clinical pharmacology.

Can CYP3A Activity Be Evaluated for Drug Interaction Using a Nanogram Dose of Probe Drug?

C. Oo, K. Duchin, 2014, Clinical pharmacology and therapeutics.

CHANGE IN CREATININE CLEARANCE WITH ADVANCING AGE

C. Oo, G. Hill, Baolin Liu, 2002, Journal of the American Geriatrics Society.

Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses

M. Kurowski, C. Oo, H. Wiltshire, 2004, Clinical drug investigation.

Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children

P. Ward, R. Dutkowski, C. Oo, 2001, Paediatric drugs.

Clonazepam and sertraline: absence of drug interaction in a multiple-dose study.

P. Bonate, P. Kroboth, E. Suárez, 2000, Journal of clinical psychopharmacology.

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Zhihua Lv, P. Zhu, C. Oo, 2022, Clinical Pharmacokinetics.

Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin

P. Ward, Baolian Liu, C. Oo, 2002, Antimicrobial Agents and Chemotherapy.

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii

Z. Lv, C. Oo, S. Sy, 2022, Frontiers in Microbiology.

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1–5 years

P. Ward, Baolian Liu, C. Oo, 2003, European Journal of Clinical Pharmacology.

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

Zhihua Lv, Xiaoqian Tang, P. Zhu, 2022, Frontiers in Microbiology.

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Zhihua Lv, P. Zhu, C. Oo, 2022, Clinical Pharmacokinetics.

Fixed-dose combinations: a potential means to boost drug development for selected drugs.

C. Oo, S. Sy, 2017, Drug discovery today.

Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults

M. Saag, J. Kilby, C. Oo, 2000, Antimicrobial Agents and Chemotherapy.

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

P. Ward, T. Cihlar, E. Ho, 2002, Drug metabolism and disposition: the biological fate of chemicals.

In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

Y. Kanai, C. Oo, B. Shah, 2014, Xenobiotica; the fate of foreign compounds in biological systems.

Safety and Pharmacology of Oseltamivir in Clinical Use

P. Ward, R. Dutkowski, C. Oo, 2003, Drug safety.

Reciprocating dialysis tube method: periodic tapping improved in vitro release/dissolution testing of suppositories.

T. Takagi, C. Oo, Kousuke Okamoto, 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Effect of Orlistat, a Novel Anti-Obesity Agent, on the Pharmacokinetics and Pharmacodynamics of Pravastatin in Patients with Mild Hypercholesterolaemia

C. Oo, B. Akbari, C. P. Hellmann, 1999 .

Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

C. Oo, S. S. Kalbag, 2016, Expert review of clinical pharmacology.

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules.

I. Wilding, Baolian Liu, C. Oo, 2003, International journal of pharmaceutics.

A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats.

C. Oo, S. Itoh, 2010, Journal of pharmaceutical sciences.

The Need for Multiple Doses of 400 mg Ketoconazole as a Precipitant Inhibitor of a CYP3A Substrate in an In Vivo Drug‐Drug Interaction Study

C. Oo, Ya-Chi Chen, 2009, Journal of clinical pharmacology.

QT Correction: Using an Observed Regression Factor Applicable to a Population Subset.

C. Oo, S. S. Kalbag, 2016, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic

C. Oo, B. Ameer, 2021, Drug Discovery Today.

Population Pharmacokinetics of the Selective Serotonin 5-HT1A Receptor Partial Agonist Piclozotan

J. Barrett, D. Patel, C. Oo, 2009, American journal of therapeutics.

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective.

C. Oo, S. Sy, 2019, Drug discovery today.

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

C. Oo, R. Noveck, 2019, Therapeutic Innovation & Regulatory Science.

Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids.

C. Oo, A. Dorr, J. Barrett, 2002, British Journal of Clinical Pharmacology.

Pharmacokinetics in lactating women: prediction of alprazolam transfer into milk.

P. McNamara, C. Oo, R. Kuhn, 1995, British journal of clinical pharmacology.

Proposed Strategies for the Integration of Genomics in Primary Care.

C. Oo, R. Noveck, 2016, The American journal of medicine.